Mark Velleca is President and Chief Executive Officer of Black Diamond Therapeutics, Inc. (BDTX). The company reported total compensation of $2,234,919 for fiscal year 2025.
| Salary | $667,400 |
|---|---|
| Bonus | $0 |
| Stock awards | $189,000 |
| Option awards | $1,006,030 |
| Non-equity incentive plan | $348,717 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $23,772 |
| Total | $2,234,919 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Black Diamond Therapeutics, Inc. filed April 29, 2026, accession 0001104659-26-051474.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Velleca this page | President and Chief Executive Officer | $2,234,919 |
| Sergey Yurasov | Chief Medical Officer | $1,352,097 |
| Brent Hatzis-Schoch | Chief Operating Officer and General Counsel | $1,282,245 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Black Diamond Therapeutics, Inc. compensation brief.
Mark Velleca's compensation sits inside Black Diamond Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Black Diamond Therapeutics, Inc. (BDTX) compensation brief